Guizhou Yibai Pharmaceutical Co Ltd (600594) - Total Liabilities
Based on the latest financial reports, Guizhou Yibai Pharmaceutical Co Ltd (600594) has total liabilities worth CN¥1.16 Billion CNY (≈ $169.24 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore 600594 net asset momentum to track the company's year-over-year net asset growth rate.
Guizhou Yibai Pharmaceutical Co Ltd - Total Liabilities Trend (2001–2025)
This chart illustrates how Guizhou Yibai Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See 600594 cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Guizhou Yibai Pharmaceutical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guizhou Yibai Pharmaceutical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thaicom Public Company Limited
BK:THCOM
|
Thailand | ฿5.46 Billion |
|
Bhagiradha Chemicals & Industries Limited
NSE:BHAGCHEM
|
India | Rs4.22 Billion |
|
XMax Inc.
NASDAQ:XWIN
|
USA | $4.70 Million |
|
Hanwha Corp Preferred
KO:00088K
|
Korea | ₩237.85 Trillion |
|
Tarczynski S.A.
WAR:TAR
|
Poland | zł1.47 Billion |
|
Hillstone Networks Co Ltd
SHG:688030
|
China | CN¥1.18 Billion |
|
Maha Energy AB (publ)
ST:MAHA-A
|
Sweden | Skr16.64 Million |
|
Zhejiang Extek Technology Co. Ltd. A
SHE:301399
|
China | CN¥170.66 Million |
Liability Composition Analysis (2001–2025)
This chart breaks down Guizhou Yibai Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 600594 market cap.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.54 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.34 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guizhou Yibai Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guizhou Yibai Pharmaceutical Co Ltd (2001–2025)
The table below shows the annual total liabilities of Guizhou Yibai Pharmaceutical Co Ltd from 2001 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.17 Billion ≈ $171.39 Million |
-21.58% |
| 2024-12-31 | CN¥1.49 Billion ≈ $218.56 Million |
-5.41% |
| 2023-12-31 | CN¥1.58 Billion ≈ $231.06 Million |
-5.78% |
| 2022-12-31 | CN¥1.68 Billion ≈ $245.23 Million |
+11.31% |
| 2021-12-31 | CN¥1.51 Billion ≈ $220.31 Million |
-14.61% |
| 2020-12-31 | CN¥1.76 Billion ≈ $258.02 Million |
-6.95% |
| 2019-12-31 | CN¥1.89 Billion ≈ $277.29 Million |
-26.12% |
| 2018-12-31 | CN¥2.56 Billion ≈ $375.34 Million |
+0.47% |
| 2017-12-31 | CN¥2.55 Billion ≈ $373.58 Million |
+6.54% |
| 2016-12-31 | CN¥2.40 Billion ≈ $350.64 Million |
+17.60% |
| 2015-12-31 | CN¥2.04 Billion ≈ $298.16 Million |
-1.63% |
| 2014-12-31 | CN¥2.07 Billion ≈ $303.10 Million |
+63.30% |
| 2013-12-31 | CN¥1.27 Billion ≈ $185.61 Million |
+73.44% |
| 2012-12-31 | CN¥731.33 Million ≈ $107.02 Million |
+9.89% |
| 2011-12-31 | CN¥665.51 Million ≈ $97.38 Million |
-3.38% |
| 2010-12-31 | CN¥688.82 Million ≈ $100.80 Million |
+20.58% |
| 2009-12-31 | CN¥571.26 Million ≈ $83.59 Million |
-7.95% |
| 2008-12-31 | CN¥620.62 Million ≈ $90.82 Million |
+1.70% |
| 2007-12-31 | CN¥610.24 Million ≈ $89.30 Million |
+8.53% |
| 2006-12-31 | CN¥562.27 Million ≈ $82.28 Million |
-13.85% |
| 2005-12-31 | CN¥652.65 Million ≈ $95.50 Million |
+80.74% |
| 2004-12-31 | CN¥361.10 Million ≈ $52.84 Million |
+31.35% |
| 2003-12-31 | CN¥274.93 Million ≈ $40.23 Million |
+57.22% |
| 2002-12-31 | CN¥174.87 Million ≈ $25.59 Million |
+29.36% |
| 2001-12-31 | CN¥135.18 Million ≈ $19.78 Million |
-- |
About Guizhou Yibai Pharmaceutical Co Ltd
Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatic bone, digestive system… Read more